v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Cash flows from operating activities:          
Net loss     $ (6,879,221) $ (7,171,529)  
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization     11,174 10,857  
Stock-based compensation     204,261 255,363  
Foreign currency (gain) loss $ (2,953) $ 29,124 (10,664) 80,927  
Changes in operating assets and liabilities:          
Prepaid expenses and other current and noncurrent assets     280,532 347,749  
Accounts payable     222,325 (161,605)  
Accrued expenses     136,104 (123,679)  
Net cash used in operating activities     (6,035,489) (6,761,917)  
Cash flows from investing activities:          
Purchases of property and equipment     (15,400)    
Net cash used in investing activities     (15,400)    
Cash flows from financing activities:          
Proceeds from issuance of common stock     35,598,881 459,019  
Common stock issuance costs     (2,912,439) (18,291)  
Net cash provided by financing activities     32,686,442 440,728  
Effect of exchange rate changes on cash, cash equivalents and restricted cash     (1,043) 4,006  
Change in cash, cash equivalents and restricted cash     26,634,510 (6,317,183)  
Cash, cash equivalents and restricted cash-beginning of year     14,640,533 22,890,055 $ 22,890,055
Cash, cash equivalents and restricted cash-end of period 41,275,043 16,572,872 41,275,043 16,572,872 14,640,533
Reconciliation of cash, cash equivalents and restricted cash          
Cash and cash equivalents 41,233,428 16,532,199 41,233,428 16,532,199 14,599,347
Restricted cash 41,615 40,673 41,615 40,673 41,186
Total cash, cash equivalents and restricted cash $ 41,275,043 $ 16,572,872 $ 41,275,043 16,572,872 $ 14,640,533
Non-cash investing and financing activities:          
Conversion of Series A convertible preferred stock to common stock       $ 583,702